This is an extraordinary opportunity join the efforts to develop a new class of
protein therapeutics to cure Type 1 Diabetes in laboratories of Professors John
Williams, Enrique Casimiro, and Bart Roep at the Beckman Research Institute and
the Diabetes & Metabolism Research Institute at the City of Hope, a world class
institute that played essential roles in the development and translation of
recombinant insulin and humanization of monoclonal antibodies and continues to
lead in the development CAR T cell and other novel therapeutic approaches. The
project will involve the rational design, production and characterization of
novel biologics using technologies pioneered in the Williams lab and
discoveries made in the Roep/Casimiro Labs. It is anticipated that the
successful applicants will have the opportunity to participate in and translate
their leads through pre-clinical development (see
https://www.cityofhope.org/news/city-of-hope-sets-new-goal-for-type-1-diabetes-cure).
Responsibilities:
Protein engineering, production, purification
Biophysical characterization (SPR, ITC, AUC, CD)
Assay development, interpretation, and troubleshooting
Minimum Education and Skills Required for Consideration:
PhD in biochemistry, molecular biology, protein chemistry, biochemical
engineering or related field.
Experience with protein expression and purification
Excellent written and verbal communication skills
Good problem solving skills
Ability to conduct independent research
Ability to supervise others and work effectively in a team
Industrial experience a plus
Apply at:
https://chm.tbe.taleo.net/chm04/ats/careers/v2/viewRequisition?org=CITYOFHOPE&cws=49&rid=10137
---------------------------------------------------------------------
-SECURITY/CONFIDENTIALITY WARNING-
This message (and any attachments) are intended solely for the individual or
entity to which they are addressed. This communication may contain information
that is privileged, confidential, or exempt from disclosure under applicable
law (e.g., personal health information, research data, financial information).
Because this e-mail has been sent without encryption, individuals other than
the intended recipient may be able to view the information, forward it to
others or tamper with the information without the knowledge or consent of the
sender. If you are not the intended recipient, or the employee or person
responsible for delivering the message to the intended recipient, any
dissemination, distribution or copying of the communication is strictly
prohibited. If you received the communication in error, please notify the
sender immediately by replying to this message and deleting the message and any
accompanying files from your system. If, due to the security risks, you do not
wish to receive further communications via e-mail, please reply to this message
and inform the sender that you do not wish to receive further e-mail from the
sender. (LCP301)
---------------------------------------------------------------------
